HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register.

Abstract
Patients with venous thromboembolism (VTE) should receive a decision on the duration of anticoagulant treatment (AT) that is often not easy to make. Sixteen Italian clinical centers included patients with recent VTE in the START2-POST-VTE register and reported the decisions taken on duration of AT in each patient and the reasons for them. At the moment of this report, 472 (66.9%) of the 705 patients included in the registry were told to stop AT in 59.3% and to extend it in 40.7% of patients. Anticoagulant treatment lasted ≥3 months in >90% of patients and was extended in patients with proximal deep vein thrombosis because considered at high risk of recurrence or had thrombophilic abnormalities. d-dimer testing, assessment of residual thrombus, and patient preference were also indicated among the criteria influencing the decision. In conclusion, Italian doctors stuck to the minimum 3 months AT after VTE, while the secondary or unprovoked nature of the event was not seen as the prevalent factor influencing AT duration which instead was the result of a complex and multifactorial evaluation of each patient.
AuthorsEmilia Antonucci, Ludovica Migliaccio, Maria Abbattista, Antonella Caronna, Sergio De Marchi, Angela Di Giorgio, Rosella Di Giulio, Teresa Lerede, Maria Grazia Garzia, Ida Martinelli, Daniela Mastroiacovo, Marco Marzolo, Elisa Montevecchi, Daniele Pastori, Pasquale Pignatelli, Daniela Poli, Luigi Ria, Angelo Santoliquido, Sophie Testa, Gualtiero Palareti, START POST VTE Investigators
JournalClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (Clin Appl Thromb Hemost) 2020 Jan-Dec Vol. 26 Pg. 1076029620945792 ISSN: 1938-2723 [Electronic] United States
PMID33063530 (Publication Type: Journal Article)
Topics
  • Aged
  • Decision Making (physiology)
  • Humans
  • Middle Aged
  • Registries
  • Risk Factors
  • Venous Thromboembolism (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: